尼可刹米在慢性阻塞性肺疾病合并肺性脑病中的应用

发布时间：2018-09-16 22:07

【摘要】：目的探讨尼可刹米在无创正压通气(NIPPV)治疗慢性阻塞性肺疾病(COPD)合并肺性脑病中的应用价值。方法选择86例COPD合并肺性脑病患者,随机分为治疗组和对照组各43例。两组均予抗感染、祛痰、抗炎、解痉等常规治疗及NIPPV,治疗组加用呼吸兴奋剂尼可刹米,以5 mg/min的速度持续泵入,连用72 h。比较两组患者血气分析、住院时间及临床转归。结果治疗后两组患者动脉血气及格拉斯哥评分(GCS评分)均较治疗前改善(P0.05),治疗组改善优于对照组(P0.05),治疗组气管插管率低于对照组(P0.05),无创通气时间(好转脱机)及平均住院时间短于对照组(P0.05),死亡率低于对照组(P0.05)。结论在NIPPV的基础上加用尼可刹米,可改善COPD合并肺性脑病患者的预后,具有良好的治疗作用。
[Abstract]:Objective to evaluate the value of nikethamil in the treatment of chronic obstructive pulmonary disease (COPD) complicated with pulmonary encephalopathy by non-invasive positive pressure ventilation (NIPPV). Methods 86 COPD patients with pulmonary encephalopathy were randomly divided into treatment group (n = 43) and control group (n = 43). Both groups were treated with anti-infection, expectorant, anti-inflammatory, antispasmodic and other routine treatment and NIPPV, treatment group with respiratory stimulant nikethamil, which was continuously pumped in at 5 mg/min for 72 hours. Blood gas analysis, hospitalization time and clinical outcome were compared between the two groups. Results after treatment, arterial blood gas and Glasgow score (GCS) were improved in both groups (P0.05), the improvement in treatment group was better than that in control group (P0.05), the rate of tracheal intubation in treatment group was lower than that in control group (P0.05), the time of noninvasive ventilation (improvement of weaning), and The average hospitalization time was shorter than that in the control group (P0.05), and the mortality was lower than that in the control group (P0.05). Conclusion the addition of nikethamil on the basis of NIPPV can improve the prognosis of patients with COPD complicated with pulmonary encephalopathy and has a good therapeutic effect.
【作者单位】：上海交通大学附属第六人民医院呼吸内科;中南大学湘雅三医院呼吸内科;
【分类号】：R563.9;R747.9

【相似文献】